<DOC>
	<DOCNO>NCT00954525</DOCNO>
	<brief_summary>Eligible candidate adult metastatic pancreatic cancer ( confirm diagnosis pathology report measurable compute tomography ( CT ) magnetic resonance imaging ( MRI ) ) . Participants must receive concurrent chemotherapy , radiation therapy . Full inclusion/exclusion criterion available . History physical examination , laboratory imaging analyse do within 14 day prior registration . The three cohort subject receive 50 , 75 100 gram intravenous ascorbic acid , three time per week 8 week . Subjects also co-administration chemotherapy medication , gemcitabine ( intravenously ) erlotinib ( orally ) . Approximately 9 18 participant enrol Phase I study .</brief_summary>
	<brief_title>Intravenous Vitamin C Combination With Standard Chemotherapy Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Metastatic pancreatic cancer Glucose 6 phosphate dehydrogenase status normal ECOG performance status 02 Normal creatinine transaminase Women childbearing potential confirm negative pregnancy test Concurrent chemotherapy radiotherapy Significant comorbid disorder Significant psychiatric symptom Prior treatment gemcitabine Concurrent chronic use immunosuppressive agent ( methotrexate , cyclosporine , corticosteroid ) Regular use nonsteroidal antiinflammatory agent Smoking 1 pack per day Excessive alcohol drug use Enrollment experimental therapy Active infection Patients experience ongoing response recent treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Pancreatic Cancer</keyword>
</DOC>